Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$16 Mln
Revenue (TTM)
$20 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.4
Industry P/E
37.53
EV/EBITDA
12.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.5
Face value
--
Shares outstanding
5,894,460
CFO
$39.43 Mln
EBITDA
$42.67 Mln
Net Profit
$13.88 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Psychemedics (PMD)
| -- | -15.7 | -7.4 | -41.2 | -34.3 | -25.8 | -17.8 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Psychemedics (PMD)
| -39.6 | -30.2 | 38.9 | -43.3 | -38.2 | -20.0 | -14.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Psychemedics (PMD)
|
2.1 | 15.7 | 20.3 | -3.0 | -11.5 | -51.1 | -- | 2.4 |
| 14.3 | 6,044.5 | 2,463.7 | -61.2 | 0.9 | -2.2 | -- | 2.2 |
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It... offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas. Read more
President, CEO & Director
Mr. Brian Hullinger
President, CEO & Director
Mr. Brian Hullinger
Headquarters
Dallas, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Psychemedics Corporation (PMD) is $2.14 (NASDAQ) as of 10-Jan-2025 09:30 EDT. Psychemedics Corporation (PMD) has given a return of -34.34% in the last 3 years.
Since, TTM earnings of Psychemedics Corporation (PMD) is negative, P/E ratio is not available.
The P/B ratio of Psychemedics Corporation (PMD) is 2.40 times as on 10-Jan-2025, a 24 discount to its peers’ median range of 3.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-4.14
|
2.58
|
|
2022
|
-25.94
|
2.61
|
|
2021
|
-59.01
|
3.21
|
|
2020
|
-7.30
|
2.25
|
|
2019
|
34.94
|
3.20
|
The 52-week high and low of Psychemedics Corporation (PMD) are Rs -- and Rs -- as of 05-Apr-2026.
Psychemedics Corporation (PMD) has a market capitalisation of $ 16 Mln as on 10-Jan-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Psychemedics Corporation (PMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.53
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.